chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, Interchange of vaccine products, SARS-CoV-2 test
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; Dose 1: Pfizer, Dose 2: Moderna, Dose 3: Pfizer; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 67-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 06Oct2022 as dose 3 (booster), single (Lot number: GH9702) at the age of 66 years for COVID-19 immunisation; BNT162b2 (BNT162B2), on 02Oct2021 as dose 1, single (Batch/Lot number: unknown), in left arm for COVID-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 24May2022 as dose 2, single (Lot number: 057M214), in right arm for COVID-19 immunisation. The patient's relevant medical history included: "Arthritis" (unspecified if ongoing); "Osteoporosis" (unspecified if ongoing); "Known allergies: Soy" (unspecified if ongoing); "Known allergies: Dairy" (unspecified if ongoing); "Known allergies: Wheat" (unspecified if ongoing); "Known allergies: Eggs" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 24May2022, outcome "unknown", described as "Dose 1: Pfizer, Dose 2: Moderna, Dose 3: Pfizer"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (2023) Positive; (06Jul2023) Negative; (07Jul2023) Negative; (09Jul2023) Positive. Therapeutic measures were taken as a result of drug ineffective, COVID-19. Clinical course: The event was treated with Paxlovid (lot number: GG0163) from 01Jul2023 to 05Jul2023. The patient tested negative of COVID-19 on 06Jul2023 and 07Jul2023. Rebound of COVID-19, positive again on 09Jul2023. The following medications was taken by the patient: N-Acetyl Cysteine (Country Life, lot number: 22C620A) from 01Jul2023 to 08Jul2023, Vit C And D from 01Jul2023 to 09Jul2023, and Zinc Lozenges (Nature's Way, lot number: 20168173) from 01Jul2023 to 08Jul2023.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300246185 same patient and drug; different dose and event;
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: Covid-19 treatment; Covid-19 treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 63-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 22Mar2021 at 10:00 as dose 1, single (Lot number: EP7534), in left arm, on 12Apr2021 at 10:00 as dose 2, single (Lot number: EW0158), in left arm, on 15Dec2021 at 10:00 as dose 3 (booster), single (Lot number: PD0809), in left arm and on 25May2022 at 10:00 as dose 4 (booster), single (Lot number: FJ4989) at the age of 62 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Penicillin" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jun2023, outcome "unknown" and all described as "Covid-19 treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19 which included Paxlovid treatment from 28Jun2023 to 03Jul2023.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300246180 same patient, different drug/ event;
Age: 51.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 51-year-old male patient received BNT162b2 (BNT162B2), in Aug2022 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 51 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jun2023, outcome "recovered" (Jul2023) and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Jun2023) Positive, notes: Treatment of COVID-19. Therapeutic measures were taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300247247 Same patient, different drug, different event;
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, Interchange of vaccine products, SARS-CoV-2 test
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; Pfizer, Dose Number: 1, 2 / Moderna, Dose Number: 3, 4; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 43-year-old male patient received BNT162b2 (BNT162B2), on 06Apr2021 as dose 1, single (Lot number: EP7533), in left arm and on 27Apr2021 as dose 2, single (Lot number: EW0175) at the age of 41 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 23Nov2021 as dose 3 (booster), single (Lot number: 018F21A), in left arm for covid-19 immunisation; davesomeran, elasomeran (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), on 11Nov2022 as dose 4 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Attention deficit hyperactivity disorder" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Bacitracin, reaction(s): "Allergic to bacitracin". The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 23Nov2021, outcome "not recovered", described as "Pfizer, Dose Number: 1, 2 / Moderna, Dose Number: 3, 4"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures (Paxlovid from 01Jul2023 to 06Jul2023) were taken as a result of drug ineffective, covid-19.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300247274 same reporter/patient, different product/AE;
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Eye irritation
Clinical narrative: eye lids burned after each shot. Pretty badly.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 57-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 14Jan2022 as dose 3 (booster), single (Lot number: 33025BD) at the age of 56 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: latex" (unspecified if ongoing), notes: Known allergies: latex. There were no concomitant medications. Past drug history included: Albuterol, reaction(s): "Known allergies: Albuterol", notes: Known allergies: Albuterol. Vaccination history included: BNT162b2 (Dose 2; lot number: EW0173; dose vaccine location: Right arm), administration date: 07May2021, when the patient was 55-year-old, for COVID-19 immunization, reaction(s): "My eye lids burned after each shot. Pretty badly."; BNT162b2 (Dose 1; lot number: EW0164; dose vaccine location: Left arm), administration date: 16Apr2021, when the patient was 55-year-old, for COVID-19 Immunization, reaction(s): "My eye lids burned after each shot. Pretty badly.". The following information was reported: EYE IRRITATION (non-serious), outcome "not recovered", described as "eye lids burned after each shot. Pretty badly.". Additional information: Patient's eye lids burned after each shot. Pretty badly. 1st occurrence, they made her sit with the paramedics for a bit. After each subsequent shot, the patient knew it would pass so did not report. Now, all this time later, every single time she cry or her eyes get watery, her tears still burn her eyelids. Pretty significantly, to the point that she have to wipe them away or it's unbearable.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300247349 Same patient, same event, same product, different dose (Dose 1);US-PFIZER INC-202300247350 Same patient, same event, same product, different dose (Dose 2);
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Body temperature, Dizziness, Fatigue, Headache
Clinical narrative: Headache; Upset Stomach; Nausea feeling; Dizziness; fever; Tiredness; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID. The reporter is the patient.  A 71-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), in Jul2023 as dose 5 (booster), single (Lot number: GK0928) at the age of 71 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), administration date: Mar2021, when the patient was 69 years old, for COVID-19 immunization, reaction(s): "never had this before with any of the others"; Bnt162b2 (DOSE 2, SINGLE), for COVID-19 immunization; Bnt162b2 (DOSE 3 (BOOSTER), SINGLE), for COVID-19 immunization; Bnt162b2 (DOSE 4 (BOOSTER), SINGLE), for COVID-19 immunization. The following information was reported: DIZZINESS (non-serious) with onset Jul2023, outcome "not recovered"; HEADACHE (non-serious) with onset Jul2023, outcome "unknown"; NAUSEA (non-serious) with onset Jul2023, outcome "not recovered", described as "Nausea feeling"; FATIGUE (non-serious) with onset Jul2023, outcome "unknown", described as "Tiredness"; ABDOMINAL DISCOMFORT (non-serious) with onset Jul2023, outcome "unknown", described as "Upset Stomach"; PYREXIA (non-serious) with onset Jul2023, outcome "unknown", described as "fever". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Patient reported that she just had the latest Pfizer vaccine shot a week ago today and feeling some things. She wanted to check if she had to be concerned. She was calling about the Pfizer Covid vaccine. She stated she cannot read "his" writing but her paper says it was "Bivalent GK0928." She stated she has had all of them, this was supposed to be her last one that the doctor said she should have. She had the 4 prior Pfizer Covid vaccines starting in Mar2021. However, this vaccine, the Pfizer Covid Bivalent vaccine, that she received a week ago was the one one that has given her these side effects. She stated she never had this before with any of the others. She received this from a pharmacy. She read the paper and knows these are possible side effects of the vaccine. This was a exactly week ago today that she received the vaccine so she wanted to know at what point she should be concerned. How long are these side effects for. She asked if she should give it more time? She was mostly concerned with the dizziness and nausea slowing her up and she was not able to do her job.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pyrexia
Clinical narrative: Headache; Upset Stomach; Nausea feeling; Dizziness; fever; Tiredness; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID. The reporter is the patient.  A 71-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), in Jul2023 as dose 5 (booster), single (Lot number: GK0928) at the age of 71 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), administration date: Mar2021, when the patient was 69 years old, for COVID-19 immunization, reaction(s): "never had this before with any of the others"; Bnt162b2 (DOSE 2, SINGLE), for COVID-19 immunization; Bnt162b2 (DOSE 3 (BOOSTER), SINGLE), for COVID-19 immunization; Bnt162b2 (DOSE 4 (BOOSTER), SINGLE), for COVID-19 immunization. The following information was reported: DIZZINESS (non-serious) with onset Jul2023, outcome "not recovered"; HEADACHE (non-serious) with onset Jul2023, outcome "unknown"; NAUSEA (non-serious) with onset Jul2023, outcome "not recovered", described as "Nausea feeling"; FATIGUE (non-serious) with onset Jul2023, outcome "unknown", described as "Tiredness"; ABDOMINAL DISCOMFORT (non-serious) with onset Jul2023, outcome "unknown", described as "Upset Stomach"; PYREXIA (non-serious) with onset Jul2023, outcome "unknown", described as "fever". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Patient reported that she just had the latest Pfizer vaccine shot a week ago today and feeling some things. She wanted to check if she had to be concerned. She was calling about the Pfizer Covid vaccine. She stated she cannot read "his" writing but her paper says it was "Bivalent GK0928." She stated she has had all of them, this was supposed to be her last one that the doctor said she should have. She had the 4 prior Pfizer Covid vaccines starting in Mar2021. However, this vaccine, the Pfizer Covid Bivalent vaccine, that she received a week ago was the one one that has given her these side effects. She stated she never had this before with any of the others. She received this from a pharmacy. She read the paper and knows these are possible side effects of the vaccine. This was a exactly week ago today that she received the vaccine so she wanted to know at what point she should be concerned. How long are these side effects for. She asked if she should give it more time? She was mostly concerned with the dizziness and nausea slowing her up and she was not able to do her job.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Crying, Eyelid irritation, Lacrimation increased
Clinical narrative: eye lids burned after each shot pretty badly/tears still burn her eyelids pretty significantly; cry; eyes get watery; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP). The reporter is the patient.  A 57-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 07May2021 as dose 2, single (batch/lot number: EW0173) at the age of 55 years, in right arm for covid-19 immunization. The patient's relevant medical history included: "latex allergies" (unspecified if ongoing). There were no concomitant medications. Past drug history included: Albuterol, reactions: "allergies". Vaccination history included: BNT162b2 (dose 1, batch/lot number EW0164, location left arm), administration date: 16Apr2021, when the patient was 55-year-old, for Covid-19 immunization, reactions: "eye lids burned, pretty badly". The following information was reported: EYELID IRRITATION (medically significant), outcome "unknown", described as "eye lids burned after each shot pretty badly/tears still burn her eyelids pretty significantly"; CRYING (non-serious), outcome "unknown", described as "cry"; LACRIMATION INCREASED (non-serious), outcome "unknown", described as "eyes get watery". Clinical course: The patient informed that her eye lids burned after each shot pretty badly. The patient informed that with the first occurrence, they made her sit with the paramedics for a bit. After each subsequent shot, she knew it would pass so did not report. Now, all this time later, every single time she cry or her eyes get watery, her tears still burn her eyelids pretty significantly to the point that she has to wipe them away or it's unbearable.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300247350 same patient/product, different dose;US-PFIZER INC-202300247305 same patient/product, different dose;
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Eye irritation
Clinical narrative: My eye lids burned after each shot.  Pretty badly.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 16Apr2021 as dose 1, single (Lot number: EW0164) at the age of 55 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "known allergies: latex" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Albuterol, reaction(s): "known allergies: Albuterol". The following information was reported: EYE IRRITATION (non-serious) with onset 2021, outcome "unknown", described as "My eye lids burned after each shot.  Pretty badly.".; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300247349 same reporter/patient/product/event, different dose;US-PFIZER INC-202300247305 same reporter/patient/product/event, different dose;
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Ear infection, Ear pain
Clinical narrative: lost of taste; ear infection; ear pain; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID: (RA). The reporter is the patient.  A 66-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot Number: SR2583), for COVID-19 immunization.  The following information was reported: AGEUSIA (non-serious), outcome "unknown", described as "lost of taste"; EAR INFECTION (non-serious), outcome "unknown"; EAR PAIN (non-serious), outcome "unknown".  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: Drug ineffective; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 45-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 26Sep2022 as dose 4 (booster), single (Lot number: GJ3277) at the age of 44 years intramuscular, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "COVID" (unspecified if ongoing), notes: If COVID prior vaccination Yes; "Known allergies: Azithromycin" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: COVID-19 (medically significant) with onset 06Jul2023, outcome "recovering"; DRUG INEFFECTIVE (medically significant) with onset 06Jul2023, outcome "recovering". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (10Jul2023) Positive, notes: Nasal Swab. Therapeutic measures were not taken as a result of drug ineffective, covid-19. Clinical course: Vaccine was obtained at pharmacy or drug store. No other vaccine was obtained in four weeks.
Age: 10.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: COVID; COVID; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP).  An 11-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 20Dec2022 as dose 4 (orange cap; booster), single (Lot number: GK1657) at the age of 10 years intramuscular, in left arm for COVID-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for COVID-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing); "COVID" (unspecified if ongoing), notes: prior to vaccination. Concomitant medication included: FLOVENT. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 09Jul2023, outcome "recovering" and all described as "COVID". The event "covid" required physician office visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (09Jul2023) Positive. Therapeutic measures were taken as a result of drug ineffective, COVID-19. Additional information: Treatment included Tessalon pearls (cough) and Flonase (congestion). The patient has no known allergies.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Vaccination failure
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 22Sep2022 at 14:00 as dose 5 (booster), single (Batch/Lot number: unknown), in left arm and on 15May2023 at 14:00 as dose 6 (booster), single (Batch/Lot number: unknown) at the age of 70 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 27Jan2021 at 09:00 as dose 1, single (Batch/Lot number: unknown), in left arm, on 20Feb2021 at 09:00 as dose 2, single (Batch/Lot number: unknown), in left arm, on 26Sep2021 at 11:00 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm and on 31Mar2022 at 15:00 as dose 4 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Allergic reaction to analgesics/oxycodone allergy" (unspecified if ongoing); "TURP", start date: 15Jun2023, stop date: 15Jun2023. The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Jun2023, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of vaccination failure, covid-19. Clinical Course: Patient received Paxlovid treatment from 22Jun2023 to 26Jun2023.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5, BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300247505 Same Patient/different drug/AE;
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Interchange of vaccine products, Vaccination failure
Clinical narrative: Interchange of vaccine products; COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 71-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 10Nov2022 as dose 5 (booster), single (Lot number: GJ3275), in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 09Feb2021 as dose 1, single (Batch/Lot number: unknown), in left arm and on 02Mar2021 as dose 2, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 01Dec2021 as dose 3 (booster), single (Lot number: 058H21A), in left arm and on 09Aug2022 as dose 4 (booster), single (Lot number: 055A22A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypothyroidism" (unspecified if ongoing). Concomitant medication(s) included: LEVOTHYROXINE, start date: 01Jun2023, stop date: 10Jul2023. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Jun2023, outcome "recovering" and all described as "COVID 19 Treatment"; INTERCHANGE OF VACCINE PRODUCTS (medically significant), outcome "recovering". Therapeutic measures were taken as a result of vaccination failure, covid-19 with Paxlovid. Clinical course: Patient started taking Paxlovid on 2nd day of symptoms and positive testing. Experienced only mild symptoms while taking Paxlovid. After the 5-day treatment, she began to experience moderate symptoms for another 10 days. She was still test positive 2 weeks after starting the Paxlovid.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300247506 Same Patient, different drug/events;
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, Interchange of vaccine products, SARS-CoV-2 test
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; Interchange of vaccine products; This is a spontaneous report received from contactable reporter(s) (Physician). The reporter is the patient.  A 69-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 18Dec2020 as dose 1, single (Lot number: EJ1685), in right arm, on 08Jan2021 as dose 2, single (Lot number: EK9231), in right arm and on 11Oct2021 as dose 3 (booster), single (Lot number: FF2589) at the age of 69 years, in right arm for covid-19 immunisation; davesomeran, elasomeran (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), on 09Nov2022 at 12:15 as dose 5 (booster), single (Lot number: 0131122A), in right arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 31May2022 at 12:30 as dose 4 (booster), single (Lot number: 049121A), in right arm for covid-19 immunisation. The patient's relevant medical history included: "Breast Cancer" (unspecified if ongoing); "B 12 Deficiency" (unspecified if ongoing); "Vitamin D deficiency" (unspecified if ongoing). Concomitant medication(s) included: VITAMIN D [VITAMIN D NOS], start date: 01Jun2018; VITAMIN B 12 [VITAMIN B12 NOS], start date: Aug2020. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 31May2022 at 12:30, outcome "unknown"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (2023) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19 which included treatment with paxlovid from 03Jul2023 to 08Jul2023.; Sender's Comments: Based on known drug safety profile, there is reasonable possibility of causal association between the events (INTERCHANGE OF VACCINE PRODUCTS,DRUG INEFFECTIVE,COVID-19) and BNT162B2.,Linked Report(s) : US-PFIZER INC-202300247494 Same Patient, different drug/AE;
Sex: M
Vaccine: UNK
Symptoms: Alanine aminotransferase increased, Aspartate aminotransferase increased, Bilirubin conjugated, Blood alkaline phosphatase increased, Blood bilirubin
Clinical narrative: Physical Exam: General appearance - alert, well appearing, and in no distress Abdomen - soft, nontender, nondistended, no masses or organomegaly     Selected Results: Last CBC    Recent Labs   07/07/23 0621 WBC 5.2 HGB 9.9* HCT 29.9* PLT 656*   Last Chem 7    Recent Labs   07/07/23 0621 NA 142 K 3.8 CL 108 CO2 23* BUN 16 CR 1.56* RBS 91   Last LFT    Recent Labs   07/07/23 0621 ALT 59* AST 65* ALKP 802* TBILI 3.9* BILIDIRECT 2.4* LIPASE 32   Last Coags    Recent Labs   07/07/23 0621 PT 12.9 INR 1.0       Assessment and Plan: 57/M with PMH of CVA with residual deficits, CKD, HTN, CAD with stents on Brilinta, CKD, diabetes, s/p cholecystectomy for biliary colic (2/28/2023), cholangiocarcinoma s/p EUS / ERCP with Spyglass and confirmatory biopsy at on 3/7/23, s/p repeat ERCP with switch plastic stent to 10 X 60 mm uncovered metal stent 4/2023 as intraductal RFA ablation felt to be of low additive benefit, who was admitted 7/3 with fever, increased LFTs, proximal  proximal biliary ductal dilation, though stent has pneumobilia.  Discovered to incidentally have COVID 19 though CXR normal and remains on room air.  Pt placed on IV zosyn.  GI consulted for further management.  Pt's ASA and Brilinta has been held since 7/3.    Impression Cholangiocarcinoma s/p uncovered metal biliary stent placement 4/2023.    ERCP on 7/5 showed tissue ingrowth at the proximal margin of the stent.  A second 10 x 60 mm uncovered metal stent was deployed overlapping with the first stent.  Some pus encountered on balloon sweep in addition to blood clots and debris, so would favor at least 7 days of antibiotics   TBili downtrended today to 3.9 (from 6.4)   No abdominal pain.  Tolerating regular diet.     Recommend: Continue to monitor liver tests, H&H Continue IV Zosyn?at least 7 days of antibiotics in total given some pus swept out of the bile duct . Switch to PO Cipro/Flagyl on discharge Follow up blood cultures from 7/3, no growth to date. Okay to try resuming Brilinta in addition to baby aspirin plan for d/c today. OK to d/c from a GI perspective. GI will sign off. Please call back if with questions.                 Note Details  Author File Time 7/7/2023  4:17 PM Author Type Physician Status Signed Last Editor  Specialty Gastroenterology Hospital Admit Date 7/3/2023  ED to Hosp-Admission (Discharged) on 7/3/2023  ED to Hosp-Admission (Discharged) on 7/3/2023   Detailed Report  Note shared with patient Care Timeline  07/04   Admitted from ED 0144 07/05   RETROGRADE CHOLANGIOPANCREATOGRAPHY ENDOSCOPIC 07/07   Discharged 1300  pt not vaccinated
Sex: M
Vaccine: UNK
Symptoms: Blood chloride increased, Blood creatinine increased, Blood glucose normal, Blood potassium normal, Blood sodium normal
Clinical narrative: Physical Exam: General appearance - alert, well appearing, and in no distress Abdomen - soft, nontender, nondistended, no masses or organomegaly     Selected Results: Last CBC    Recent Labs   07/07/23 0621 WBC 5.2 HGB 9.9* HCT 29.9* PLT 656*   Last Chem 7    Recent Labs   07/07/23 0621 NA 142 K 3.8 CL 108 CO2 23* BUN 16 CR 1.56* RBS 91   Last LFT    Recent Labs   07/07/23 0621 ALT 59* AST 65* ALKP 802* TBILI 3.9* BILIDIRECT 2.4* LIPASE 32   Last Coags    Recent Labs   07/07/23 0621 PT 12.9 INR 1.0       Assessment and Plan: 57/M with PMH of CVA with residual deficits, CKD, HTN, CAD with stents on Brilinta, CKD, diabetes, s/p cholecystectomy for biliary colic (2/28/2023), cholangiocarcinoma s/p EUS / ERCP with Spyglass and confirmatory biopsy at on 3/7/23, s/p repeat ERCP with switch plastic stent to 10 X 60 mm uncovered metal stent 4/2023 as intraductal RFA ablation felt to be of low additive benefit, who was admitted 7/3 with fever, increased LFTs, proximal  proximal biliary ductal dilation, though stent has pneumobilia.  Discovered to incidentally have COVID 19 though CXR normal and remains on room air.  Pt placed on IV zosyn.  GI consulted for further management.  Pt's ASA and Brilinta has been held since 7/3.    Impression Cholangiocarcinoma s/p uncovered metal biliary stent placement 4/2023.    ERCP on 7/5 showed tissue ingrowth at the proximal margin of the stent.  A second 10 x 60 mm uncovered metal stent was deployed overlapping with the first stent.  Some pus encountered on balloon sweep in addition to blood clots and debris, so would favor at least 7 days of antibiotics   TBili downtrended today to 3.9 (from 6.4)   No abdominal pain.  Tolerating regular diet.     Recommend: Continue to monitor liver tests, H&H Continue IV Zosyn?at least 7 days of antibiotics in total given some pus swept out of the bile duct . Switch to PO Cipro/Flagyl on discharge Follow up blood cultures from 7/3, no growth to date. Okay to try resuming Brilinta in addition to baby aspirin plan for d/c today. OK to d/c from a GI perspective. GI will sign off. Please call back if with questions.                 Note Details  Author File Time 7/7/2023  4:17 PM Author Type Physician Status Signed Last Editor  Specialty Gastroenterology Hospital Admit Date 7/3/2023  ED to Hosp-Admission (Discharged) on 7/3/2023  ED to Hosp-Admission (Discharged) on 7/3/2023   Detailed Report  Note shared with patient Care Timeline  07/04   Admitted from ED 0144 07/05   RETROGRADE CHOLANGIOPANCREATOGRAPHY ENDOSCOPIC 07/07   Discharged 1300  pt not vaccinated
Sex: M
Vaccine: UNK
Symptoms: Blood urea normal, Carbon dioxide normal, Coagulation test abnormal, Full blood count abnormal, Haematocrit decreased
Clinical narrative: Physical Exam: General appearance - alert, well appearing, and in no distress Abdomen - soft, nontender, nondistended, no masses or organomegaly     Selected Results: Last CBC    Recent Labs   07/07/23 0621 WBC 5.2 HGB 9.9* HCT 29.9* PLT 656*   Last Chem 7    Recent Labs   07/07/23 0621 NA 142 K 3.8 CL 108 CO2 23* BUN 16 CR 1.56* RBS 91   Last LFT    Recent Labs   07/07/23 0621 ALT 59* AST 65* ALKP 802* TBILI 3.9* BILIDIRECT 2.4* LIPASE 32   Last Coags    Recent Labs   07/07/23 0621 PT 12.9 INR 1.0       Assessment and Plan: 57/M with PMH of CVA with residual deficits, CKD, HTN, CAD with stents on Brilinta, CKD, diabetes, s/p cholecystectomy for biliary colic (2/28/2023), cholangiocarcinoma s/p EUS / ERCP with Spyglass and confirmatory biopsy at on 3/7/23, s/p repeat ERCP with switch plastic stent to 10 X 60 mm uncovered metal stent 4/2023 as intraductal RFA ablation felt to be of low additive benefit, who was admitted 7/3 with fever, increased LFTs, proximal  proximal biliary ductal dilation, though stent has pneumobilia.  Discovered to incidentally have COVID 19 though CXR normal and remains on room air.  Pt placed on IV zosyn.  GI consulted for further management.  Pt's ASA and Brilinta has been held since 7/3.    Impression Cholangiocarcinoma s/p uncovered metal biliary stent placement 4/2023.    ERCP on 7/5 showed tissue ingrowth at the proximal margin of the stent.  A second 10 x 60 mm uncovered metal stent was deployed overlapping with the first stent.  Some pus encountered on balloon sweep in addition to blood clots and debris, so would favor at least 7 days of antibiotics   TBili downtrended today to 3.9 (from 6.4)   No abdominal pain.  Tolerating regular diet.     Recommend: Continue to monitor liver tests, H&H Continue IV Zosyn?at least 7 days of antibiotics in total given some pus swept out of the bile duct . Switch to PO Cipro/Flagyl on discharge Follow up blood cultures from 7/3, no growth to date. Okay to try resuming Brilinta in addition to baby aspirin plan for d/c today. OK to d/c from a GI perspective. GI will sign off. Please call back if with questions.                 Note Details  Author File Time 7/7/2023  4:17 PM Author Type Physician Status Signed Last Editor  Specialty Gastroenterology Hospital Admit Date 7/3/2023  ED to Hosp-Admission (Discharged) on 7/3/2023  ED to Hosp-Admission (Discharged) on 7/3/2023   Detailed Report  Note shared with patient Care Timeline  07/04   Admitted from ED 0144 07/05   RETROGRADE CHOLANGIOPANCREATOGRAPHY ENDOSCOPIC 07/07   Discharged 1300  pt not vaccinated
Sex: M
Vaccine: UNK
Symptoms: Haemoglobin decreased, International normalised ratio normal, Lipase normal, Liver function test abnormal, Metabolic function test abnormal
Clinical narrative: Physical Exam: General appearance - alert, well appearing, and in no distress Abdomen - soft, nontender, nondistended, no masses or organomegaly     Selected Results: Last CBC    Recent Labs   07/07/23 0621 WBC 5.2 HGB 9.9* HCT 29.9* PLT 656*   Last Chem 7    Recent Labs   07/07/23 0621 NA 142 K 3.8 CL 108 CO2 23* BUN 16 CR 1.56* RBS 91   Last LFT    Recent Labs   07/07/23 0621 ALT 59* AST 65* ALKP 802* TBILI 3.9* BILIDIRECT 2.4* LIPASE 32   Last Coags    Recent Labs   07/07/23 0621 PT 12.9 INR 1.0       Assessment and Plan: 57/M with PMH of CVA with residual deficits, CKD, HTN, CAD with stents on Brilinta, CKD, diabetes, s/p cholecystectomy for biliary colic (2/28/2023), cholangiocarcinoma s/p EUS / ERCP with Spyglass and confirmatory biopsy at on 3/7/23, s/p repeat ERCP with switch plastic stent to 10 X 60 mm uncovered metal stent 4/2023 as intraductal RFA ablation felt to be of low additive benefit, who was admitted 7/3 with fever, increased LFTs, proximal  proximal biliary ductal dilation, though stent has pneumobilia.  Discovered to incidentally have COVID 19 though CXR normal and remains on room air.  Pt placed on IV zosyn.  GI consulted for further management.  Pt's ASA and Brilinta has been held since 7/3.    Impression Cholangiocarcinoma s/p uncovered metal biliary stent placement 4/2023.    ERCP on 7/5 showed tissue ingrowth at the proximal margin of the stent.  A second 10 x 60 mm uncovered metal stent was deployed overlapping with the first stent.  Some pus encountered on balloon sweep in addition to blood clots and debris, so would favor at least 7 days of antibiotics   TBili downtrended today to 3.9 (from 6.4)   No abdominal pain.  Tolerating regular diet.     Recommend: Continue to monitor liver tests, H&H Continue IV Zosyn?at least 7 days of antibiotics in total given some pus swept out of the bile duct . Switch to PO Cipro/Flagyl on discharge Follow up blood cultures from 7/3, no growth to date. Okay to try resuming Brilinta in addition to baby aspirin plan for d/c today. OK to d/c from a GI perspective. GI will sign off. Please call back if with questions.                 Note Details  Author File Time 7/7/2023  4:17 PM Author Type Physician Status Signed Last Editor  Specialty Gastroenterology Hospital Admit Date 7/3/2023  ED to Hosp-Admission (Discharged) on 7/3/2023  ED to Hosp-Admission (Discharged) on 7/3/2023   Detailed Report  Note shared with patient Care Timeline  07/04   Admitted from ED 0144 07/05   RETROGRADE CHOLANGIOPANCREATOGRAPHY ENDOSCOPIC 07/07   Discharged 1300  pt not vaccinated
Sex: M
Vaccine: UNK
Symptoms: Platelet count increased, Prothrombin time prolonged, Purulent discharge, Thrombosis, White blood cell count normal
Clinical narrative: Physical Exam: General appearance - alert, well appearing, and in no distress Abdomen - soft, nontender, nondistended, no masses or organomegaly     Selected Results: Last CBC    Recent Labs   07/07/23 0621 WBC 5.2 HGB 9.9* HCT 29.9* PLT 656*   Last Chem 7    Recent Labs   07/07/23 0621 NA 142 K 3.8 CL 108 CO2 23* BUN 16 CR 1.56* RBS 91   Last LFT    Recent Labs   07/07/23 0621 ALT 59* AST 65* ALKP 802* TBILI 3.9* BILIDIRECT 2.4* LIPASE 32   Last Coags    Recent Labs   07/07/23 0621 PT 12.9 INR 1.0       Assessment and Plan: 57/M with PMH of CVA with residual deficits, CKD, HTN, CAD with stents on Brilinta, CKD, diabetes, s/p cholecystectomy for biliary colic (2/28/2023), cholangiocarcinoma s/p EUS / ERCP with Spyglass and confirmatory biopsy at on 3/7/23, s/p repeat ERCP with switch plastic stent to 10 X 60 mm uncovered metal stent 4/2023 as intraductal RFA ablation felt to be of low additive benefit, who was admitted 7/3 with fever, increased LFTs, proximal  proximal biliary ductal dilation, though stent has pneumobilia.  Discovered to incidentally have COVID 19 though CXR normal and remains on room air.  Pt placed on IV zosyn.  GI consulted for further management.  Pt's ASA and Brilinta has been held since 7/3.    Impression Cholangiocarcinoma s/p uncovered metal biliary stent placement 4/2023.    ERCP on 7/5 showed tissue ingrowth at the proximal margin of the stent.  A second 10 x 60 mm uncovered metal stent was deployed overlapping with the first stent.  Some pus encountered on balloon sweep in addition to blood clots and debris, so would favor at least 7 days of antibiotics   TBili downtrended today to 3.9 (from 6.4)   No abdominal pain.  Tolerating regular diet.     Recommend: Continue to monitor liver tests, H&H Continue IV Zosyn?at least 7 days of antibiotics in total given some pus swept out of the bile duct . Switch to PO Cipro/Flagyl on discharge Follow up blood cultures from 7/3, no growth to date. Okay to try resuming Brilinta in addition to baby aspirin plan for d/c today. OK to d/c from a GI perspective. GI will sign off. Please call back if with questions.                 Note Details  Author File Time 7/7/2023  4:17 PM Author Type Physician Status Signed Last Editor  Specialty Gastroenterology Hospital Admit Date 7/3/2023  ED to Hosp-Admission (Discharged) on 7/3/2023  ED to Hosp-Admission (Discharged) on 7/3/2023   Detailed Report  Note shared with patient Care Timeline  07/04   Admitted from ED 0144 07/05   RETROGRADE CHOLANGIOPANCREATOGRAPHY ENDOSCOPIC 07/07   Discharged 1300  pt not vaccinated
Age: 55.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Patient recieved the Shingrix series twice. First series (dose 1 and 2) administered on 5/12/2018 and 7/14/2018. Series administered again by mistake on 1/26/23 (dose 1) and 3/31/23 (dose 2). Patient did not report any adverse effects or issues.
Age: 26.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Pneumonia, Sepsis
Clinical narrative: Assessment and Plan:   Patient with recently diagnosed large B-cell lymphoma (primary mediastinal lymphoma versus gray zone lymphoma).   Admitted for pneumonia and COVID infection with sepsis without organ dysfunction. Patient is status post cycle 1 of DA?R EPOCH?R chemotherapy.  On G-CSF support.  Counts are stable. Agree with aggressive antimicrobial therapy.  Expect counts to decline over the next few days with subsequent recovery.  Continue to monitor. Plan for CT chest next week Friday.     Note Details  Author  (M.D.) File Time 7/7/2023 10:34 AM Author Type Physician Status Signed
Age: 13.0
Sex: F
Vaccine: MENB
Symptoms: Extra dose administered
Clinical narrative: GIVEN EXTRA DOSE OF MEN ACWY.  REPORTED TO VAERS.  CONTACTED PATIENT TO COME IN FOR SECOND MEN B ON JULY 13, 2023.
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Dyspnoea, Injection site erythema, Injection site swelling, Pneumonia, Pyrexia
Clinical narrative: patient received vaccine on 6/29/23. Patient reported to the pharmacist on 7/6/23 saying she had redness swelling around site and fevers. patient stated she had hard time breathing so she went to the ER which they admitted her for pneumonia or UTI based infection. This seems likely she had a concurrent infection manifesting when she came in but reported to us on 7/6/23 about an adverse event and this issue so we are reporting it.  Patient was told that fever redness and swelling is common but the breathing issues is not. We have no access to hospital notes and per patient stating it maybe due to vaccine we are submitting this report
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Urinary tract infection
Clinical narrative: patient received vaccine on 6/29/23. Patient reported to the pharmacist on 7/6/23 saying she had redness swelling around site and fevers. patient stated she had hard time breathing so she went to the ER which they admitted her for pneumonia or UTI based infection. This seems likely she had a concurrent infection manifesting when she came in but reported to us on 7/6/23 about an adverse event and this issue so we are reporting it.  Patient was told that fever redness and swelling is common but the breathing issues is not. We have no access to hospital notes and per patient stating it maybe due to vaccine we are submitting this report
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Balance disorder, Computerised tomogram, Hemiparesis, Laboratory test, Magnetic resonance imaging
Clinical narrative: Thalamus stroke Visual disturbances, loss of balance, excessive sleepiness, garbled speech, left sided weakness
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Somnolence, Thalamic infarction, Thalamic stroke, Visual impairment, X-ray
Clinical narrative: Thalamus stroke Visual disturbances, loss of balance, excessive sleepiness, garbled speech, left sided weakness
Age: 23.0
Sex: M
Vaccine: COVID19-2
Symptoms: Blood glucose, Blood pressure decreased, Dyspnoea, Hypoaesthesia, Malaise
Clinical narrative: At around 6:20 PM, on duty administered the Covid-19 Bivalent vaccine to the patient. This is the very first Covid-19 vaccine the patient has ever received. After administered the vaccine, asked for patient to sit on one of the chairs at the pharmacy waiting area for 15 minutes. At around 6:30 pm his brother came to the consultation window and said he was not feeling well. Then checked up on the patient who appeared very pale. Asked about his symptoms to which patient said he felt like his extremities were tingling and numb, it was difficult for him to breathe, everything was bright around him so he closed his eyes. Immediately called the ambulance. Patient asked for a bottle of water.  While waiting for EMS, patient said he was feeling slowly better. When EMS came, they took down his vitals. The lead paramedic recommended for him to go to the hospital but the patient declined. The parademic then called a nurse and informed her of patient's decision. Nurse then asked to speak to patient on the phone who asked several follow up questions. Prior to leaving, EMS asked for a signature to waive liability. Patient felt a lot better after the interaction with the pharmacist and paramedics. Informed patient to call the pharmacy if he has any further questions.
Age: 23.0
Sex: M
Vaccine: COVID19-2
Symptoms: Pallor, Paraesthesia, Visual brightness
Clinical narrative: At around 6:20 PM, on duty administered the Covid-19 Bivalent vaccine to the patient. This is the very first Covid-19 vaccine the patient has ever received. After administered the vaccine, asked for patient to sit on one of the chairs at the pharmacy waiting area for 15 minutes. At around 6:30 pm his brother came to the consultation window and said he was not feeling well. Then checked up on the patient who appeared very pale. Asked about his symptoms to which patient said he felt like his extremities were tingling and numb, it was difficult for him to breathe, everything was bright around him so he closed his eyes. Immediately called the ambulance. Patient asked for a bottle of water.  While waiting for EMS, patient said he was feeling slowly better. When EMS came, they took down his vitals. The lead paramedic recommended for him to go to the hospital but the patient declined. The parademic then called a nurse and informed her of patient's decision. Nurse then asked to speak to patient on the phone who asked several follow up questions. Prior to leaving, EMS asked for a signature to waive liability. Patient felt a lot better after the interaction with the pharmacist and paramedics. Informed patient to call the pharmacy if he has any further questions.
Age: 39.0
Sex: M
Vaccine: TD
Symptoms: Injection site pain, Pain in extremity, Skin warm, Swelling, Tenderness
Clinical narrative: Large amount of swelling, tenderness, within hour of injection. Left shoulder/arm pain. Got worse over several days. Swelling didn?t start to go down for three plus weeks.  Very warm to touch. Sent picture to clinic. Recommended appt. I was seen in clinic. Given script for 5 days prednisone. Got shoulder x ray. Pain and swelling went down, briefly. Seen orthopedics, swelling is down now but 3 out of 10 or more pain persists to this day.
Age: 67.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: NONE - Vaccine given beyond use date pt had no adverse events
Age: 72.0
Sex: M
Vaccine: COVID19-2
Symptoms: No adverse event, Product use issue
Clinical narrative: NONE - Vaccine given beyond use date pt had no adverse events
Age: 74.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: NONE - Vaccine given beyond use date pt had no adverse events
Age: 68.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: NONE - Vaccine given beyond use date pt  had no adverse events